NASDAQ: NKGNNkgen Biotech Inc Stock
$1.85+0.38 (+25.85%)
Updated Apr 23, 2024
NKGN Price
$1.85
Fair Value Price
-$1.27
Market Cap
$42.19M
52 Week Low
$0.78
52 Week High
$12.88
P/E
-0.34x
P/B
-0.72x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$82.95M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.28
Operating Cash Flow
-$22M
Beta
0.33
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NKGN Overview
Graf Acquisition Corp. IV is a "blank check" company formed to effect mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations. It targets companies in industries such as mobility, technology, transportation, new energy, software, business real estate services, financial and data services, healthcare, diversified industrial manufacturing, and technology. Graf Acquisition Corp. IV was incorporated in 2021 and is based in The Woodlands, TX.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NKGN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NKGN ($1.85) is overvalued by 245.28% relative to our estimate of its Fair Value price of -$1.27 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NKGN ($1.85) is not significantly undervalued (245.28%) relative to our estimate of its Fair Value price of -$1.27 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NKGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NKGN due diligence checks available for Premium users.
Be the first to know about important NKGN news, forecast changes, insider trades & much more!
NKGN News
Valuation
NKGN fair value
Fair Value of NKGN stock based on Discounted Cash Flow (DCF)
Price
$1.85
Fair Value
-$1.27
Undervalued by
245.28%
NKGN ($1.85) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NKGN ($1.85) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NKGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NKGN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.34x
Industry
16.46x
Market
41.92x
NKGN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.72x
Industry
5.93x
NKGN's financial health
Profit margin
Revenue
$0.0
Net Income
-$33.6M
Profit Margin
0%
NKGN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$16.5M
Liabilities
$75.2M
Debt to equity
-1.28
NKGN's short-term liabilities ($39.45M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NKGN's long-term liabilities ($35.72M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NKGN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NKGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.9M
Investing
-$18.0k
Financing
-$1.8M
NKGN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NKGN vs Biotech Stocks
Nkgen Biotech Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.